Alembic Pharmaceuticals has said the US health regulator has granted fast track designation to its associate company Rhizen Pharmaceuticals SA’s RP6530 (tenalisib) used in the treatment of cancer.
“The US Food and Drug Administration (USFDA) has granted fast track designation for RP6530 (tenalisib)...for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL),” Alembic Pharmaceuticals said in a BSE filing today.
Fast track designation is awarded to drugs that treat a serious condition and fill an unmet medical need, it added.
Shares of Alembic Pharmaceuticals were trading down by 0.07 per cent at Rs 514.35 on the BSE.